Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02550847

Enrollment

100

Registered

2015-09-16

Start date

2014-08-31

Completion date

2016-08-31

Last updated

2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

MR/PET, pancreatic cancer

Brief summary

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Detailed description

The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

Interventions

DEVICEThe imaging biomarkers determined by MR-PET

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Diagnosed as pancreatic cancer 2. Between 20\ 90 years old 3. ECOG 0-2 4. Normal renal function 5. Measurable tumor size (\>1cm)

Exclusion criteria

1. Contraindication for MRI exam 2. Claustrophobia 3. Renal insufficiency 4. Other malignancy 5. Pregnancy and lactating women

Design outcomes

Primary

Measure	Time frame
The tumor recurrence rate after operation at 6 months	6 months

Secondary

Measure	Time frame
The overall survival after operation at 6 months	6 months

Countries

Taiwan

Contacts

Primary ContactTing-Fang Shih, MD

ttfshih@ntu.edu.tw+886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026